Neumora Therapeutics Inc(NMRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:02 PM ET (Korea 10/29 06:02)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.23 | Insider Own | 57.8% | Shs Outstand | 186.8M | Perf Week | -5.5% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 30.06% | Insider Trans | -0.42% | Shs Float | 79.3M | Perf Month | -41.99% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.2 | Inst Own | 26.95% | Short Float | 7.11% | Perf Quarter | -76.18% |
| Income | -0.21B | P/S | - | EPS this Y | 37.34% | Inst Trans | 3.38% | Short Ratio | 3.95 | Perf Half Y | -82.53% |
| Sales | 0.00B | P/B | 1.65 | EPS next 5Y | 22.14% | ROA | -121.89% | Short Interest | 5.64M | Perf YTD | -78.04% |
| Book/sh | 0.24 | P/C | 0.63 | EPS past 3/5Y | -18.95% -17.29% | ROE | -187.11% | 52W High | -89.23% ($3.65) | Perf Year | -84.82% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | -218.26% | 52W Low | 24.64% ($0.32) | Perf 3Y | -96.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.31% | Gross Margin | - | Volatility(W/M) | 14.87% 14.59% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.5 | EPS Q/Q | 28.64% | Profit Margin | - | RSI (14) | 31.38 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.5 | Sales Q/Q | - | SMA20 | -10.89% ($0.44) | Beta | 3.03 | Target Price | $6.67 |
| Payout | - | Debt/Eq | 1.2 | Earnings | 2026/8/14 | SMA50 | -53.23% ($0.83) | Rel Volume | 0.78 | Prev Close | $0.37 |
| Employees | 96 | LT Debt/Eq | 1.19 | EPS/Sales Surpr. | 4.21% - | SMA200 | -78.12% ($1.78) | Avg Volume(3M) | 1.43M | Price | $0.39 |
| IPO | 2023/9/15 | Option/Short | Yes/Yes | Trades | 2776 | Volume | 1,117,992 | Change | 6.79% |
A U.S. clinical-stage biotech company developing novel therapeutics for brain disorders through a precision medicine approach. Its lead candidate, navacaprant, is a kappa opioid receptor antagonist being developed for depression, and the company has a pipeline of multiple central nervous system (CNS) programs targeting depression and Alzheimer's disease.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual. That is 78% of its average volume.
NMRA has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.3% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -96.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #386 of 594 in the industry
Based on market cap of $74M.
CING#384 Cingulate Inc $76M PER - 
TELO#385 Telomir Pharmaceuticals Inc $74M PER - NMRA#386 Neumora Therapeutics Inc $74M PER - 
MNOV#387 Medicinova Inc $72M PER - 
MAIA#388 MAIA Biotechnology Inc $72M PER - 
FAQ
What kind of company is NMRA?
NMRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NMRA?
The market cap of NMRA is approximately $74M, ranking 4,662 within its sector.
What is the 52-week high and low for NMRA?
NMRA has recorded a 52-week high of $3.65 and a low of $0.32.
